Recently, researchers have suggested an association between FGFR2b overexpression/FGFR2 amplification and intestinal phenotype and lower tumor grade (Schrumpf et al. 2022), while others have described a significant correlation with the diffuse histological type (Matsumoto et al. 2012; Ahn et al. 2016) or even no association with the histological subtype (O'Sullivan et al. 2014; Shoji et al. 2015). The gene discussed is FGFR2; the disease is neoplasm.